Pan-cancer analysis reveals PRRT4 is a potential prognostic factor of AML by Wenqiong Xiang (17738962)

“…After PRRT4 knockdown, the proliferation ability of THP1 cells was significantly enhanced, and the apoptosis ratio was significantly decreased.…”

Table 1_S-equol status modulates skin response to soy isoflavones in postmenopausal women: results from a randomized placebo-controlled pilot trial.docx by Vineetha Vijayakumar (17064126)

“…</p>Results<p>Crow’s feet wrinkle roughness decreased by 5.6% in the Novasoy®400 group versus a 1.6% increase in the placebo group, this difference was not statistically significant. …”

Data Sheet 1_OSH45, a homeobox transcription factor, coordinates low-phosphate adaptation in rice.pdf by Hong Lu (58784)

“…OSH45 overexpression transgenic plants exhibited enhanced low-Pi tolerance, characterized by significantly higher Pi concentrations and increased shoot and root biomass compared to wild type (WT) under Pi-limited conditions. …”

Table 1_Urinary and oral microbiota in Polish women: a pilot case-control study of breast cancer.docx by Anna Marciniak (12354534)

“…</p>Results<p>BC case urine microbiota contained an increased abundance of Corynebacterium (5.2-fold, but not significant) and Gammaproteobacteria including unknown genus and Pseudomonas (1.7- and 1.8-fold) and decreased abundance of Family XI (0.3-fold) and Bifidobacteriaceae (0.4-fold) compared to HCs. …”

Table 1_OSH45, a homeobox transcription factor, coordinates low-phosphate adaptation in rice.xlsx by Hong Lu (58784)

“…OSH45 overexpression transgenic plants exhibited enhanced low-Pi tolerance, characterized by significantly higher Pi concentrations and increased shoot and root biomass compared to wild type (WT) under Pi-limited conditions. …”

Table 2_OSH45, a homeobox transcription factor, coordinates low-phosphate adaptation in rice.xlsx by Hong Lu (58784)

“…OSH45 overexpression transgenic plants exhibited enhanced low-Pi tolerance, characterized by significantly higher Pi concentrations and increased shoot and root biomass compared to wild type (WT) under Pi-limited conditions. …”

Table 3_OSH45, a homeobox transcription factor, coordinates low-phosphate adaptation in rice.xlsx by Hong Lu (58784)

“…OSH45 overexpression transgenic plants exhibited enhanced low-Pi tolerance, characterized by significantly higher Pi concentrations and increased shoot and root biomass compared to wild type (WT) under Pi-limited conditions. …”

Table 4_OSH45, a homeobox transcription factor, coordinates low-phosphate adaptation in rice.xlsx by Hong Lu (58784)

“…OSH45 overexpression transgenic plants exhibited enhanced low-Pi tolerance, characterized by significantly higher Pi concentrations and increased shoot and root biomass compared to wild type (WT) under Pi-limited conditions. …”

Table 5_OSH45, a homeobox transcription factor, coordinates low-phosphate adaptation in rice.xlsx by Hong Lu (58784)

“…OSH45 overexpression transgenic plants exhibited enhanced low-Pi tolerance, characterized by significantly higher Pi concentrations and increased shoot and root biomass compared to wild type (WT) under Pi-limited conditions. …”

Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 2_Building radiomics models based on ACR TI-RADS combining clinical features for discriminating benign and malignant thyroid nodules.docx by Xingxing Chen (1569277)

“…The Clin+ACR+Rad model showed excellent diagnostic prediction ability in both the training (AUC = 0.958) and test datasets (AUC = 0.937), significantly outperforming other models including Rad-score (AUC = 0.890, 0.856), Clin+Rad (AUC = 0.895, 0.859), ACR+Rad (AUC = 0.943, 0.934), and Clin+ACR (AUC = 0.784, 0.785) (all P < 0.05). …”

Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an... by Chao Song (379006)

“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”

Image 1_Augmentation of bone formation by sympathectomy in rats as evaluated by [99mTc]Tc-MDP.png by Zili Cai (15238729)

“…SCGx rats exhibited significantly higher [^99mTc]Tc-MDP uptake and increased BMD, BV/TV, and BV in peri-fracture regions at all time points (p < 0.0001). …”